Revolution Medicines
Revolution Medicines, Inc. is an American clinical-stage oncology biopharmaceutical company focused on developing targeted therapies for RAS-addicted cancers. The enterprise develops novel small-molecule inhibitors designed to selectively target the active RAS-ON state, which drives tumor growth across various RAS-mutated solid tumors. Its pipeline features clinical candidate compounds such as elinorasib and zoldatrasib targeting pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer. As a development-stage biopharmaceutical company, it currently generates negligible commercial revenue and relies on equity financing and strategic partnerships. Revolution Medicines maintains a specialized research position in precision oncology focused on RAS pathway inhibition. The ultimate end markets for its therapeutic pipeline encompass oncologists and cancer care facilities globally. Corporate headquarters are located in Redwood City, California, United States. Revolution Medicines is listed on the Nasdaq Global Select Market.
43 of the funds FundTelligence covers report a position in Revolution Medicines.
- Legal name
- Revolution Medicines Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 43
- Exposure themes
- Precision Medicine & Genomics, Precision Oncology, Precision Therapeutics
Funds holding Revolution Medicines
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 5.1 % (partially disclosed portfolio, September 2026)
- Janus Henderson Horizon Biotechnology Fund — Janus Henderson · 4.59 % (largest positions only, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 3.38 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 2.65 % (full portfolio disclosed, October 2026)
- DNB Bioteknologi — DNB · 2.62 % (full portfolio disclosed, September 2026)
- Pensum Kairos — Pensum · 2.48 % (full portfolio disclosed, June 2026)
- HealthInvest Sustainable Healthcare — HealthInvest · 2.0 % (partially disclosed portfolio, September 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.71 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 43 funds holding it.